Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | ALPL | P05186 | 3/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | ALPG | P10696 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30864995 | 0.79 | PDE3B (0.63) | KMT2APKMMEN1LMNAALDH1A1 | |
| SCHEMBL27083368 | 0.79 | PDE3B (0.63) | KMT2APKMMEN1LMNAALDH1A1 | |
| SCHEMBL10153780 | 0.76 | SMN1; SMN2 (0.64) | KMT2AALPLALPIALPGPKM | |
| SCHEMBL9381947 | 0.76 | CDC7 (0.61) | KMT2AMEN1MAPTLMNA | |
| Benzene SCHEMBL29186724 | 0.75 | POLB (0.60) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL12633842 | 0.73 | POLB (1.00) | KMT2APKMPOLBMAPTLMNA | |
| SCHEMBL21045164 | 0.73 | KMT2A (0.52) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL17268194 | 0.72 | IL4I1 (0.56) | KMT2APOLBMEN1MAPTLMNA | |
| SCHEMBL30864989 | 0.72 | PDE3B (0.63) | KMT2APKMPOLBMEN1LMNA | |
| SCHEMBL27083348 | 0.72 | PDE3B (0.63) | KMT2APKMPOLBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | PREP, HPN, PEPD | KMT2A 3756/4885ALPL 942/4885ALPI 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.